Divis Laboratories Reports 13 PAT Growth in Q4 Declares Rs 30 Dividend ColgatePalmolive India Shifts Strategy Toward Premium Oral Care and DigitalFirst Growth CocaCola and Procter Gamble Two Dividend Stocks Under LongTerm Focus Trump Reverses AI Executive Order Dropping Safety Review Requirement for New Models Genpact CEO Says AI Could Reduce IT Workload and Jobs Requiring Higher Skill Sets LibertyStream Aims to Tap Lithium From Permian Basin Produced Water Offering Potential Domestic Supply Alternative GOODO Q1 2026 Earnings Preferred Stock Beats EPS Estimates With 5686 Surprise FHN Q1 2026 Earnings EPS Beats Estimates as Capital Strength Shines IMMP Q1 2026 Earnings EPS Misses Estimates Amid PreRevenue Phase First Mid Bancshares FMBH Q1 2026 Earnings EPS Surpasses Expectations by 531 Amid Steady Performance TG Therapeutics Q1 2026 Earnings EPS Disappoints as Stock Declines Monte Rosa Therapeutics Inc GLUE Q1 2026 Earnings WiderthanExpected Loss Compounds Investor Caution PLUS THERAPEUTICS PSTV Slips 316 as Shares Test Key Support Amid Biotech Jitters Chicago Rivet Machine Co CVR Edges Higher as Shares Test Key Resistance Level Primo Brands Corporation PRMB Holds Near 2453 as Support and Resistance Levels Tighten Stepan Company SCL Edges Higher as It Consolidates Near Support Levels Ur Energy Inc URG Jumps 516 as Uranium Sentiment Strengthens Resistance at 171 in Focus Bank of America Reaffirms Buy Rating on Netflix NFLX Stock BBU Q4 2025 Earnings Significant Earnings Miss Impacts Quarterly Results AEF Holds Steady Near Key Levels After Marginal Pullback Calisa Acquisition Corp Units ALISU Hover Near Support as Price Remains Flat Farmer Brothers FARM Holds Steady at 128 as Traders Eye Key Support and Resistance Levels Roadzen Inc RDZN Consolidates at 19 as Stock Hovers Between Key Support and Resistance ABVC BioPharma Inc ABVC Holds Near Support Showing Cautious Recovery Potential Aclarion Inc ACON Slips 156 as Shares Approach Key Support at 30 Parke Bancorp Inc PKBK Hovers Near Flatline as Traders Weigh Support and Resistance Levels Aclaris Therapeutics ACRS Edges Higher Testing Key Resistance Near 481